Ondine Biomedical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OBI.L research report →
Companywww.ondinebio.com
Ondine Biomedical Inc. , a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens.
- CEO
- Carolyn Cross
- IPO
- 2021
- Employees
- 18
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $64.25M
- P/E
- -6.29
- P/S
- 69.52
- P/B
- 166.34
- EV/EBITDA
- -6.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.92%
- Op Margin
- -1134.33%
- Net Margin
- -1127.55%
- ROE
- -506.43%
- ROIC
- -1506.81%
Growth & Income
- Revenue
- $2.05M · 70.32%
- Net Income
- $-19,098,000 · -32.51%
- EPS
- $-0.07 · 4.24%
- Op Income
- $-19,444,000
- FCF YoY
- -12.08%
Performance & Tape
- 52W High
- $18.50
- 52W Low
- $7.50
- 50D MA
- $11.95
- 200D MA
- $11.77
- Beta
- 0.27
- Avg Volume
- 403.01K
Get TickerSpark's AI analysis on OBI.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OBI.L Coverage
We haven't published any research on OBI.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OBI.L Report →